Blog Tag
5 articles tagged with Biotech Investing. The newest post is from Mar 11, 2026.
One of the easiest ways to organize biotech news is to build your coverage around company names. A company-based watchlist gives you a clear starting point because it narrows the news universe to the stocks and programs you actually care about. Instead of trying to read everything, you follow a defined set of names and let the market alert you when something changes.
A biosimilar is a biologic product that is highly similar to an already approved reference biologic, with no clinically meaningful differences in safety, purity, or potency. In biotech, biosimilars matter because they introduce competition into biologic markets that were once protected by exclusivity and patent strength.
A biosimilar is a biologic product that is highly similar to an already approved reference biologic, with no clinically meaningful differences in safety, purity, or potency. In biotech, biosimilars matter because they introduce competition into biologic markets that were once protected by exclusivity and patent strength.
A first-in-class drug is a therapy that introduces a new mechanism of action or a new way of treating a disease that has not been approved before. In biotech, the term is highly meaningful because it signals novelty. A first-in-class drug may open a completely new therapeutic path, which can create significant opportunity but also significant uncertainty.
A clinical trial readout is the public release of data from a clinical study. In biotech, the phrase usually refers to the first meaningful disclosure of results from a Phase 1, Phase 2, or Phase 3 trial. That readout may come as a company press release, a conference presentation, an abstract, an SEC filing, or a combination of sources. Regardless of format, the readout is one of the most important events in biotech because it converts scientific work into public evidence.
